FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Dilip Davda has given "May Apply" recommendation to Quest Laboratories IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 1 | 0 | 0 | 0 |
% | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Dilip Davda | May Apply |
[Dilip Davda] The company is operating in a highly competitive and fragmented segment. It posted bumper profits from FY22 onwards, that raise eyebrows and concern over its sustainability going forward. Based on FY24 annualized super earnings, the issue appears fully priced. Well-informed/cash surplus investors may park moderate funds for the medium term. Read detail review...
Quest Laboratories Limited peer comparison with similar listed entities. (As on March 31, 2023)
Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
---|---|---|---|---|---|---|---|
Quest Laboratories Limited | 4.66 | 4.66 | 13.93 | 33.47 | |||
Beta Drugs Limited | 19.57 | 19.57 | 100.12 | 66.43 | 19.55 | 12.98 | Standalone |
Alpa Laboratories Ltd. | 5.90 | 5.90 | 68.69 | 15.92 | 8.59 | 1.37 | Standalone |
Zenith Drugs Limited | 4.29 | 4.29 | 14.37 | 14.69 | 29.88 | 4.38 | Consolidated |
Notes:
Quest Laboratories IPO Reviews, analysis and views by popular members. Read Quest Laboratories Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 0 | 0 |
% |
Member | Review |
---|---|
No recommendation found. Be the first to post the
recommendation. |
Post Recommendation Manage Recommendations
Note:
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|